A new study by the non-profit Global Antibiotic Research and Development Partnership (GARDP) looked at access to antibiotics for nearly 1.5 million cases of carbapenem-resistant Gram-negative (CRGN) infections across eight major low- and middle-income countries, including India, Brazil and South Africa. CRGN bacteria are superbugs resistant to last-line antibiotics - yet only 6.9% of patients received appropriate treatment in the countries studied.

India bore the lion’s share of CRGN infections and treatment efforts, procuring 80% of the full courses of studied antibiotics but managing to treat only 7.8% of its estimated cases, the study in The Lancet Infectious Diseases journal reports. (A full drug course of antibiotics refers to the complete set of doses that a patient needs to take over a specific period to fully treat an infection.)

Common in water, food, the environment and the human gut, Gram-negative bacteria cause infections such as urinary tract infections (UTIs), pneumonia and food poisoning.

They can pose a serious threat to newborns and the elderly alike. Especially vulnerable are hospital patients with weakened immunity, often spreading rapidly in ICUs and proving difficult - and sometimes impossible - to treat. Treating carbapenem-resistant Gram-negative bacterial infections is doubly difficult because those bacteria are resistant to some of the most powerful antibiotics.

“These infections are a daily reality across all age groups,” says Dr Abdul Gaffar, infectious disease consultant at Apollo Hospital in India’s Chennai city. “We often see patients for whom no antibiotic works - and they die.”